| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 500mg | |||
| 1g |
|
| Targets |
Piperacillin Sodium targets penicillin-binding proteins (PBPs) in the bacterial cell wall. As a β-lactam antibiotic, it inhibits the transpeptidase activity of PBPs, which are essential for bacterial cell wall synthesis. This inhibition disrupts the cross-linking of peptidoglycan, leading to bacterial cell lysis and death. Its broad-spectrum activity is due to its ability to bind to multiple PBPs in both gram-negative and gram-positive bacteria.
|
|---|---|
| ln Vitro |
Piperacillin Sodium demonstrates broad-spectrum antibacterial activity in vitro against a wide range of gram-negative and gram-positive bacteria. It is active against Enterococcus species, E. coli, and Pseudomonas. Its activity is assessed by standard antimicrobial susceptibility testing methods (broth microdilution or agar diffusion). MIC values against various bacterial strains are available in the literature. It is often used in combination with tazobactam to overcome beta-lactamase-mediated resistance.
|
| ln Vivo |
Piperacillin Sodium is used clinically for the treatment of serious, hospital-acquired infections. It is used almost exclusively in combination with the beta-lactamase inhibitor tazobactam. Its in vivo efficacy has been established through clinical use. It is administered intravenously. It is active against a broad range of pathogens including Pseudomonas aeruginosa.
|
| Enzyme Assay |
Antibacterial susceptibility testing is performed using broth microdilution or agar dilution methods according to CLSI guidelines. Bacterial strains (e.g., E. coli ATCC 25922, P. aeruginosa ATCC 27853) are cultured in appropriate media. Piperacillin Sodium is serially diluted in 96-well plates or agar plates. Bacterial inoculum is added and plates are incubated at 35°C for 16-20 hours. MIC values are determined as the lowest concentration causing complete inhibition of visible growth. Quality control strains are included to ensure assay validity. Beta-lactamase production is assessed using appropriate methods.
|
| Cell Assay |
Cellular antibacterial activity is evaluated in bacterial cell cultures using standard microbiological methods. Broth microdilution assays are performed in 96-well plates with appropriate media. Bacteria are cultured to logarithmic phase and diluted to a standard inoculum. Piperacillin Sodium is serially diluted and added to wells. Plates are incubated at 35°C for 16-20 hours. MIC values are determined visually or using a microplate reader. Time-kill curve assays are performed to assess bactericidal activity. Each experiment includes quality control strains and antibiotic standards.
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of bacterial infection. Piperacillin Sodium is administered intravenously or intramuscularly at doses determined by preclinical studies. Bacterial burden is quantified in infected tissues by CFU plating. Clinical symptoms are monitored. Sample sizes typically range from 6-10 animals per group. Clinical studies have been conducted for serious hospital-acquired infections.
|
| ADME/Pharmacokinetics |
Piperacillin Sodium has a molecular weight of 539.54 g/mol and a molecular formula of C23H26N5NaO7S. Potency: 863-1007 µg/mg of piperacillin. Storage: typically at room temperature, protected from moisture. As a β-lactam antibiotic, it is administered intravenously. Pharmacokinetic parameters: it is distributed throughout the body, metabolized, and excreted renally. Half-life is approximately 1 hour.
|
| Toxicity/Toxicokinetics |
Piperacillin Sodium is generally well-tolerated at therapeutic doses. Common adverse effects may include gastrointestinal disturbances, skin rash, allergic reactions, and injection site reactions. As a penicillin antibiotic, it is contraindicated in patients with penicillin hypersensitivity. Standard toxicology studies have demonstrated an acceptable safety profile. It is approved for clinical use in many countries.
|
| References | |
| Additional Infomation |
Piperacillin sodium is an organosodium salt containing a piperacillin (1-) group. Piperacillin sodium is the sodium salt of piperacillin, a broad-spectrum, semi-synthetic, ampicillin-derived ureapeptide antibiotic with bactericidal activity. Piperacillin binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of bacterial cell walls, leading to weakening of the bacterial cell wall and cell lysis. PBPs participate in the final stages of bacterial cell wall assembly and remodel the cell wall during cell division. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains, which is essential for maintaining the strength and rigidity of the bacterial cell wall. Piperacillin sodium is a semi-synthetic, broad-spectrum, ampicillin-derived ureapeptide antibiotic intended for the treatment of Pseudomonas infections. It can also be used in combination with other antibiotics. See also: Piperacillin sodium; Tazobactam sodium (component).
Piperacillin Sodium is also known as Sodium piperacillin and T 1220. It is a semisynthetic, broad-spectrum ureidopenicillin antibiotic. It is used almost exclusively in combination with tazobactam for serious hospital-acquired infections. It is approved for clinical use in many countries. |
| Molecular Formula |
C23H26N5NAO7S
|
|---|---|
| Molecular Weight |
539.54
|
| Exact Mass |
539.145
|
| CAS # |
59703-84-3
|
| Related CAS # |
Piperacillin;61477-96-1;Piperacillin-d5
|
| PubChem CID |
23666879
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
707.1ºC at 760 mmHg
|
| Melting Point |
183-185ºC (dec.)
|
| Flash Point |
381.4ºC
|
| Index of Refraction |
180 ° (C=0.8, H2O)
|
| LogP |
0.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
37
|
| Complexity |
989
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
|
| InChi Key |
IVBHGBMCVLDMKU-GXNBUGAJSA-N
|
| InChi Code |
InChI=1S/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1
|
| Chemical Name |
(2S,5R,6R)-6-[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
|
| Synonyms |
Pipracil PIPERACILLIN SODIUM SALT Piperacillin Sodium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~185.34 mM)
H2O : ≥ 100 mg/mL (~185.34 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (185.34 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8534 mL | 9.2672 mL | 18.5343 mL | |
| 5 mM | 0.3707 mL | 1.8534 mL | 3.7069 mL | |
| 10 mM | 0.1853 mL | 0.9267 mL | 1.8534 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
